Finance Home - My Yahoo - Yahoo! - Help

Monday, November 30, 2009, 9:04AM ET - U.S. Markets open in 26 mins.. Dow  1.48% Nasdaq  0.00%

MAP Pharmaceuticals, Inc. (MAPP)

On Nov 27: 9.11   0.00 (0.00%)

MORE ON MAPP

Quotes Summary Real-Time Options Historical Prices Charts Interactive Basic Chart Basic Tech. Analysis News & Info Headlines Financial Blogs Company Events Message Board Company Profile Key Statistics SEC Filings Competitors Industry Components Analyst Coverage Analyst Opinion Analyst Estimates Research Reports Star Analysts Ownership Major Holders Insider Transactions Insider Roster Financials Income Statement Balance Sheet Cash Flow

Profile Get Profile for:
MAP Pharmaceuticals, Inc. 2400 Bayshore Parkway Suite 200 Mountain View, CA 94043-1107 United States - Map Phone: 650-386-3100 Fax: 650-386-3101 Web Site: http://www.mappharma.com DETAILS   Index Membership: N/A Sector: Healthcare Industry: Drug Manufacturers - Other Full Time Employees: 95 BUSINESS SUMMARY   MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. The company’s product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. It has a collaborations and license agreements with AstraZeneca, Elan Pharma International, Nektar Therapeutics, and Xemplar Pharmaceuticals. MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California. Key Statistics COMPANY WEBSITES   Home Page Search Yahoo! for: More on MAP Pharmaceuticals, Inc.		CORPORATE GOVERNANCE   MAP Pharmaceuticals, Inc.'s Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 61.2% of Russell 3000 companies and 66.4% of Pharmaceuticals, Biotechnology & Life Sciences companies. Brought to you by Institutional Shareholder Services. View Financials KEY EXECUTIVES     Pay Exercised Mr. Timothy S. Nelson , 45 Chief Exec. Officer, Pres $ 648.00K $ 0 Dr. Thomas A. Armer Ph.D., 55 Co-Founder, Chief Scientific Officer $ 419.00K $ 0 Mr. Christopher Y. Chai , 43 Chief Financial Officer and Principal Accounting Officer $ 393.00K $ 0 Mr. Anastasios E. Gianakakos M.Sc., MBA, 36 Sr. VP of Corp. & Bus. Devel. and Head of Respiratory Bus. Unit $ 391.00K $ 350.00K Ms. Charlene A. Friedman , 51 VP, Sec. and Gen. Counsel $ 380.00K $ 0 Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year. View Insiders
Add to Portfolio     Set Alert     Email to a Friend Get Profile for Another Symbol: Symbol Lookup • Annual Reports • Sector Analysis